New Prostatic Hyperplasia Study Results from Korea University Described (Alpha-blocker and Risk of Dementia In Patients With Benign Prostatic Hyperplasia: a Nationwide Population Based Study Using the National Health Insurance Service Database)

2019 AUG 12 (NewsRx) -- By a News Reporter-Staff News Editor at Information Technology Business Daily -- Research findings on Urogenital Diseases and Conditions - Prostatic HyperplAsia are discussed in a new report. According to news reporting originating from Ansan, South Korea, by NewsRx correspondents, research stated, “A recent study demonstrated that tamsulosin increased the risk of dementia in patients with benign prostatic hyperplasia. However, this study had a number of limitations.”

Financial supporters for this research include Korea University, Korea Urologic Association.

Our news editors obtained a quote from the research from Korea University, “We evaluated the association between alpha-blockers and dementia in patients with benign prostatic hyperplasia. From the National Health Insurance Service database we collected and analyzed data on alpha-blockers and dementia in the entire Korean adult population with benign prostatic hyperplasia between January 2011 and December 2011. These patients were followed until September 2017. We tested the effect of alpha-blockers on the risk of dementia using propensity score matched Cox proportional hazard regression models and Kaplan-Meier survival analysis. During a mean +/- SD followup of 1,580 +/- 674.3 days all study inclusion and exclusion criteria were met by 59,263 patients with benign prostatic hyperplasia. In the unadjusted cohort the incidence of dementia in the tamsulosin, doxazosin, terazosin, alfuzosin and no medication cohorts were 17.97%, 18.55%, 20.64%, 17.62% and 22.60%, respectively. After propensity score matching the risk of dementia did not significantly differ in the tamsulosin cohort vs the doxazosin and alfuzosin cohorts (HR 1.038, 95% CI 0.960-1.121 and HR 1.008, 95% CI 0.925-1.098), respectively. Compared to the tamsulosin cohort the terazosin cohort had a higher risk of dementia (HR 1.112, 95% CI 1.052-1.196). However, the risk of dementia was significantly lower in the terazosin cohort than in the no medication cohort.”

According to the news editors, the research concluded: “The study findings indicate that benign prostatic hyperplasia medication is not associated with a risk of dementia by duration of use or by type.”

For more information on this research see: Alpha-blocker and Risk of Dementia In Patients With Benign Prostatic Hyperplasia: a Nationwide Population Based Study Using the National Health Insurance Service Database. The Journal of Urology, 2019;202(2):362-368. The Journal of Urology can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA.

The news editors report that additional information may be obtained by contacting J.H. Bae, Korea University, College Of Medicine, Ansan Hospital, Dept. of Urology, 123 Jeokgeum Ro, Ansan 425707, South Korea. Additional authors for this research include B.S. Tae, B.J. Jeon, H. Choi, J.Y. Park and J. Cheon.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1097/JU.0000000000000209. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)